Dear Natalia,
thanks for your post! "Good" to read somebody with the same mutations, although I am aware that even the same mutations can make different problems.
But from what I've read so far, although both belong to the more severe classes, it looks like F508del/R553X makes more problems with the pancreas and less with the lungs. It is like this also with our daughter. With six weeks she had already elastase <50 and still we are struggling to find the right dosis with enzymes. But her lungs are free. *keep fingers crossed*
Concerning the new drugs, the big hope for our children is Ataluren. Vertex VX-770 targets people with another mutation. But there will be further trials with VX-770 and VX-809, which would help with F508del mutation. I don't know when this would be ready for the market, as they are only in phase 2. see: http://www.vrtx.com/current-projects/drug-candidates/vx-770.html
But as I wrote already in my last post, Ataluren could be on the market already in 2013!
First for children >6 years, but after more trials it will also be available for younger children! Ataluren would help with the R553X mutation!
Dear Aleksandra,
Ataluren would also help Asia, because she has the R553X mutation. The drug is designed to help with all nonsense mutations!
You can read the Q&A on the website: http://www.ptcbio.com/6.1.2_ataluren_CF_trial_FAQ.aspx#Q2
There it says that the drug will help also if somebody has only one nonsense muation. As I understood it is then comparable to a carrier, who has one mutation, but no disease.
The question that is always in my mind is how big the impact of the drug will be...
Will the CF symptoms only get milder or will they disappear completely? I know that probably nobody knows the answer yet, but I allow myself dreming, that these new drugs will "heal" our babies!